Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Safety and Efficacy of Serplulimab Plus Chemotherapy in Patients With Histological Transformation From EGFR-mutated NSCLC to SCLC After Treatment: a Single-arm, Multicenter, Open-label Phase II Study

NCT05957510 is registered in ClinicalTrials.gov with Guangdong Association of Clinical Trials as lead sponsor.

NCT NCT05957510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05957510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Safety and Efficacy of Serplulimab Plus Chemotherapy in Patients With Histological Transformation From EGFR-mutated NSCLC to SCLC After Treatment: a Single-arm, Multicenter, Open-label Phase II Study
Lead sponsor
Guangdong Association of Clinical Trials
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 7, 2023
Completion date
December 31, 2026
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small-cell lung cancer